ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -7 مورد

Vaginal hormone preparations available in the United States for treatment of genitourinary syndrome of menopause (vulvovaginal atrophy)

Vaginal hormone preparations available in the United States for treatment of genitourinary syndrome of menopause (vulvovaginal atrophy)
Preparation United States trade name Available strength(s) Suggested regimen
Estrogens
Conjugated estrogen Vaginal cream* Premarin 0.625 mg conjugated estrogens per g of cream 0.5 g of cream intravaginally administered once daily for 2 weeks, then reduce to twice weekly; dose may be adjusted according to patient's symptoms and clinical response (range: 0.5 to 2 g of cream).
Estradiol Vaginal cream* Estrace 100 mcg estradiol per g of cream 0.5 g of cream intravaginally administered once daily for 2 weeks, then reduce to twice weekly; dose may be adjusted according to patient's symptoms and clinical response (initial range: 0.5 to 4 g of cream; maintenance range: 0.5 to 1 g of cream).
Vaginal insert Imvexxy 4 mcg or 10 mcg estradiol per vaginal insert Insert 1 softgel intravaginally once daily for 2 weeks, followed by twice weekly. Initial dose depends on clinical severity and patient preference; dose may be increased or decreased according to clinical response.
Vagifem, Yuvafem 10 mcg estradiol per vaginal insert Insert 1 tablet intravaginally once daily for 2 weeks, followed by twice weekly.
Vaginal ring Estring 7.5 mcg estradiol per day, released over 90 days Ring is inserted into the vagina by the patient or clinician. Ring is removed and replaced with a new ring every 90 days.
DHEAΔ
Prasterone Vaginal insert Intrarosa 6.5 mg prasterone per vaginal insert Insert 1 suppository intravaginally once daily.
For clinical indications, refer to related UpToDate content. Product choice is often determined by patient preference and cost.

DHEA: dehydroepiandrosterone; GSM: genitourinary syndrome of menopause.

* Vaginal estrogen creams are supplied with an applicator marked with dose calibrations so the patient can measure the prescribed amount of cream.

¶ Our practice differs from the manufacturer's product information; refer to UpToDate topic for further information.

Δ While approved only for the indication of GSM-associated dyspareunia, studies have also demonstrated improvement in vaginal dryness. This is discussed in related UpToDate content.

Prepared with data from:
  1. FDA prescribing information available at US National Library of Medicine NIH DailyMed website. Available at: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on October 4, 2024).
  2. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause 2020; 27:976.
Graphic 58506 Version 28.0